AI News NQ Analysis

Croda launches highly purified amino acid series "BioXPro™" to support stable manufacturing and formulation processes for biopharmaceuticals.

NQ Score 76/100

AI Summary (NQ-processed)

Croda Japan Co., Ltd. has launched "BioXPro™," a series of highly purified amino acids designed to support stable manufacturing and formulation processes for biopharmaceuticals. This series combines Croda's advanced purification technology with insights gained from a partnership with Amino GmbH. It helps reduce lot-to-lot variability by strictly controlling levels of metals, elemental impurities, and endotoxins. Four types are available—arginine, arginine hydrochloride, histidine, and histidine hydrochloride—suitable for use from R&D to commercial manufacturing, and applicable across various processes such as cell culture, viral inactivation, and formulation.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the main purpose of Croda's BioXPro amino acid series?
A: It is designed to support stable manufacturing and formulation processes for biopharmaceuticals by acting as highly purified additives.
Q: Which company did Croda partner with to design the BioXPro series?
A: Croda combined its advanced purification technology with insights gained through a partnership with Amino GmbH.
Q: What are the four specific types of amino acids offered in the BioXPro series?
A: The series offers four types: Arginine, Arginine Hydrochloride, Histidine, and Histidine Hydrochloride.
Q: Which regions' major pharmacopoeias do the BioXPro products comply with?
A: They comply with the major pharmacopoeias in Japan, the United States, Europe, and China.
Q: How does BioXPro help reduce lot-to-lot variability in manufacturing?
A: It reduces lot-to-lot variability by managing low levels of metals, elemental impurities, and endotoxins.